SNY vs WST
Sanofi vs West Pharmaceutical Services — AI-powered side-by-side comparison
SNY
Sanofi
62
Insufficient Data
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | SNY | WST |
|---|
| AI Score |
62
|
74
|
| Price |
$43.56
|
$351.74
|
| P/E Ratio |
23.06×
|
44.65×
|
| ROE |
10.9%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.8%
|
36.8%
|
| Debt / Equity |
0.34×
|
0.10×
|
| Dividend Yield |
5.5%
|
0.3%
|
| RSI (14) |
53.1
|
58.0
|
| Beta |
0.278
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for SNY versus WST.
WST leads by 12 points.
WST scores 74/100 (Buy) versus SNY at 62/100 (Insufficient Data).
SNY Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical